EGFR and colorectal carcinoma: In contrast, microsatellite stable (MSS) BRAFV600E-mutant CRC exhibits poor responses to conventional chemotherapy, with standard regimens such as FOLFOX and FOLFIRI plus anti-EGFR antibody showing limited efficacy [14,44].